GPR17 and myeloid sarcoma: Considering GPR17 distribution in MS brain tissues, its strong correlation with inflammation levels in WM and the direct involvement in myelin genesis and repair, we confirm this receptor as a promising target for pro-remyelinating therapies, which today still represent an unmet medical need in MS treatment.